CDK4 and esophageal squamous cell carcinoma: To the best of our knowledge, this study is the first to evaluate the value of CDK4 amplification as a novel candidate prognostic biomarker in patients with ESCC, so it is necessary to further investigate the upstream and downstream genes of CDK4 to clarify its role and elucidate the prognostic utility in ESCC.